Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2
复制标题
DOI：
10.1016/j.dld.2015.12.006
复制
发表时间：
2016-04-01
影响因子：
4.5
通讯作者：
Bang, Seungmin
中科院分区：
文献类型：
--
作者：
Lee, Sang Hoon;Yoon, Sang Hyun;Bang, Seungmin
背景资料：二甲双胍对胰腺癌患者生存率的影响存在争议。目的：研究二甲双胍对胰腺癌患者的有益作用。方法：我们回顾性分析了在Severance医院接受治疗的胰腺癌和既存2型糖尿病患者。（首尔，韩国）。结果：在237例入组患者中，117例（49.4%）暴露于二甲双胍。二甲双胍组的中位总生存期为13.7个月，而非二甲双胍组为8.9个月（P = 0.001）。单因素分析显示，二甲双胍暴露、低血清碳水化合物抗原19-9水平（< 1000 U/mL）、小肿瘤大小（
Backgrounds: The effect of metformin on survival in patients with pancreatic cancer is controversial.Aims: To investigate the beneficial effect of metformin in pancreatic cancer patients.Methods: We retrospectively analyzed patients with pancreatic cancer and pre-existing diabetes mellitus type 2 who were treated at Severance Hospital (Seoul, South Korea) between May 2005 and December 2013.Results: Among 237 enrolled patients, 117 patients (49.4%) were exposed to metformin. The median overall survival was 13.7 months for the metformin group versus 8.9 months for the non-metformin group (P = 0.001) In univariate analysis, metformin exposure, low serum carbohydrate antigen 19-9 levels (< 1000 U/mL), small tumor size (